CXCR
Cat. No. | Product Name | CAS No. | Information |
---|---|---|---|
CSN15996 | WZ811 | 55778-02-4 | WZ811 is a small molecular and potency CXCR4 antagonist with EC50 of 0.3 nM. |
CSN23717 | USL311 | 1373268-67-7 | USL311 is a selective CXCR4 antagonist, with anti-tumor activity. USL311 prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4[1]. |
CSN18633 | UNBS5162 | 956590-23-1 | UNBS5162 is a naphthalimide and a hydrolysis product of UNBS3157 that decreases CXCL chemokine expression in experimental prostate cancers and the mean antiproliferative activity IC50 value is 179 M for 9 cancer cell lines |
CSN27389 | SX-682 | 1648843-04-2 | SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity. |
CSN17557 | SRT3190 | 1204707-73-2 | SRT3190 is CXCR2 ligand. |
CSN17556 | SRT3109 | 1204707-71-0 | SRT3109 is a CXCR2 ligand for use in the treatment of chemokine mediated diseases and conditions. |
CSN19351 | SCH 563705 | 473728-58-4 | SCH-563705 is a potent dual CXCR2 (IC50 1.3 nM)CXCR1 (IC50 7.3 nM) antagonist. |
CSN12829 | Navarixin | 473727-83-2 | SCH-527123 is a potent antagonist of both CXCR1 and CXCR2 with IC50 of 42 nM and 3 nM, respectively. |
CSN13174 | SCH 546738 | 906805-42-3 | SCH 546738 is a potent and non-competitive small molecule CXCR3 antagonist with Ki of 0.4 nM . |
CSN17197 | SB225002 | 182498-32-4 | SB225002 is a potent and selective non-peptide inhibitor of CXCR2 with IC50 of 22 nM, showing 150-fold selectivity over CXCR1 and four other 7-TMRs. |
CSN23103 | SB-332235 | 276702-15-9 | SB-332235 is a potent and specific CXCR2 antagonist. SB-332235 effectively inhibited CS-induced neutrophilia in a dose-dependent manner. |
CSN23101 | SB-265610 | 211096-49-0 | SB-265610 is a potent CXCR2 antagonist that inhibits CINC-1-mediated but not C5a-mediated Ca2+ mobilization (IC50 values are 3.4 and 6800 nM respectively). It inhibits CINC-induced chemotaxis and attenuates neutrophil accumulation in inflammatory lung injury in vivo. |
CSN18171 | Reparixin L-lysine salt | 266359-93-7 | Reparixin L-lysine is an inhibitor of CXCL8 receptor, also inhibit CXCR1 and CXCR2 activation,which has been shown to attenuate inflammatory responses in various injury models. |
CSN15950 | Reparixin | 266359-83-5 | Reparixin is an inhibitor of CXCL8 receptor, also inhibit CXCR1 and CXCR2 activation, which has been shown to attenuate inflammatory responses in various injury models. |
CSN12664 | Plerixafor | 110078-46-1 | Plerixafor is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively. |
CSN16151 | Plerixafor octahydrochloride | 155148-31-5 | Plerixafor 8HCl is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively. |
CSN23012 | NVP CXCR2 20 | 1029521-30-9 | NVP CXCR2 20 is a potent and selective CXCR2 antagonist with IC50 of 40 nM. |
CSN18477 | NBI-74330 | 855527-92-3 | NBI-74330 is a small molecule antagonist for CXCR3, NBI-74330 demonstrates potent inhibition of (125)ICXCL10 and (125)ICXCL11 specific binding (K (i) of 1.5 and 3.2 nM, respectively. |
CSN21269 | MSX-130 | 4051-59-6 | MSX-130 is CXCR4 Antagonist |
CSN32932 | Ladarixin sodium | 865625-56-5 | Ladarixin Sodium is a CXCR antagonist potentially for the treatment of type I diabetes. |
CSN32931 | Ladarixin | 849776-05-2 | Ladarixin is a dual, non-competitive, allosteric inhibitor of CXCR1 and CXCR2 interleukin-8 (IL-8A and IL-8B, respectively). |
CSN24505 | JMS-17-2 | 1380392-05-1 | JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. |
CSN22862 | IT1t dihydrochloride | 1092776-63-0 | IT1t 2HCl is a potent CXCR4 antagonist with IC50 of 1.1 nM. |
CSN18630 | Danirixin | 954126-98-8 | Danirixin is a small molecule, non-peptide, high affinity (IC50 for CXCL8 binding 12.5 nM), selective, and reversible CXCR2 antagonist. |
CSN26625 | CXCR7 modulator 2 | 2227426-37-9 | CXCR7 modulator 2 is a modulator of C-X-C Chemokine Receptor Type 7 (CXCR7), with a Ki of 13 nM. |
CSN32401 | Burixafor | 1191448-17-5 | Burixafor is an orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4) with receptor binding and hematopoietic stem cell-mobilization activities. |
CSN15665 | Baohuoside I | 113558-15-9 | Baohuoside I, a flavonoid, acts as an apoptosis inducer and a down-regulator of durvivin and cyclin D1 expression. It is used as an anti-cancer agent and can be isolated and purified from the roots of epimedium brevicornu Maxim. |
CSN21987 | AZD8797 | 911715-90-7 | AZD8797 is an allosteric non-competitive and orally active modulator of the human CX3CR1 receptor which antagonizes CX3CR1 and CXCR2 with Kis of 3.9 and 2800 nM, respectively. |
CSN22921 | AZD-5069 | 878385-84-3 | AZD 5069 is a selective and reversible antagonist of CXCR2 that can inhibit CXCL8 binding to CXCR2 with pIC50 of 91 |
CSN18287 | AMG 487 | 473719-41-4 | AMG-487 is a small molecule antagonist of the chemokine receptor CXCR3 and inhibits binding of 125I-IP-10 and 125I-ITAC to CXCR3. |
CSN13161 | Mavorixafor | 558447-26-0 | AMD-070 is a potent and selective antagonist of CXCR4 with an IC50 value of 13 nM in a CXCR4 125I-SDF inhibition binding assay, and inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs. |
CSN24435 | Mavorixafor trihydrochloride | 2309699-17-8 | AMD-070 is a potent and selective antagonist of CXCR4 with an IC50 value of 13 nM in a CXCR4 125I-SDF inhibition binding assay, and inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs. |
CSN13824 | (S)-N1-((1H-Benzo[d]imidazol-2-yl)methyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine hydrochloride | 880549-30-4 | AMD-070 HCl is a potent and selective antagonist of CXCR4 with an IC50 value of 13 nM in a CXCR4 125I-SDF inhibition binding assay and inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs. |
CSN18051 | AMD 3465 | 185991-24-6 | AMD 3465 is a potent, selective CXCR4 antagonist and exhibits 8-fold higher affinity than AMD 3100 and inhibits SDF-1-ligand binding (Ki 41.7 nM). |
CSN16529 | AMD 3465 hexahydrobromide | 185991-07-5 | AMD 3465 hexahydrobromide is a potent, selective CXCR4 antagonist and exhibits 8-fold higher affinity than AMD 3100 and inhibits SDF-1-ligand binding (Ki 41.7 nM). |
CSN22618 | (±)-AMG 487 | 947536-03-0 | (±)-AMG 487 is an antagonist of CXCR3 that inhibits binding of 125I-IP-10 and 125I-ITAC to CXCR3 with IC50 of 8.0 and 8.2 nM respectively. |
CSN73217 | (E)-N-(3-(2-Fluorophenyl)-2-methylallyl)-3,4,5-trimethoxy-N-(2-(1-methylpyrrolidin-2-yl)ethyl)benzamide | 1378524-41-4 | |
CSN83400 | CCX-777 | 1226686-36-7 |